Operational Update
IXICO plc has appointed two prominent global experts, Professor Michael Weiner and Professor Joanna Wardlaw, to its Scientific Advisory Board, bolstering its strategy in Alzheimer's Disease and vascular biomarker development. These appointments, announced at the CTAD conference, align with IXICO's focus on AI-driven drug development for neurological disorders, particularly in identifying and measuring vascular abnormalities which are common contributors to neurodegenerative diseases. The company is already deploying its first vascular biomarker algorithm to clients for clinical trials, with further releases planned within the current financial year, aiming to enhance trial design and interpretability of efficacy results.
Select text to share a quote on X · sign in to keep highlights & notes in your IXI notes
-Appointments announced at 2025 CTAD Conference form part of a concerted dementia research and product innovation strategy, particularly in the area of vascular biomarkers -
01 December 2025, IXICO plc (AIM: IXI) - London, UK. IXICO, a global leader in neuroscience imaging and biomarker analytics, using its AI-driven platform to help advance drug development in neurological disorders, today announced that it has appointed two leading global experts in the field of Alzheimer's Disease (AD) and cerebrovascular disease (CVD) as advisors to the Company. Professor Michael Weiner, and Professor Joanna Wardlaw join IXICO's advisory board with immediate effect.
The announcement is being made as part of IXICO's participation in the 18th CTAD conference (Clinical Trials on Alzheimer's Disease) which starts today. CTAD is an annual cornerstone event in Alzheimer's Diseases (AD) clinical research, where IXICO will be presenting research on its capabilities for the accurate assessment of positron emission tomography (PET) imaging in clinical trials.
Professor Micheal Weiner, MD.
Michael is a Professor Emeritus in Radiology and Biomedical Imaging, Medicine, Psychiatry, and Neurology at the University of California, San Francisco. He is Principal Investigator of the Alzheimer's Disease Neuroimaging Initiative (ADNI), which is the largest observational study in the world concerning Alzheimer's Disease. Michael's full biography is available in the notes at the bottom of this announcement.
Professor Joanna Wardlaw, MD, CBE.
Joanna is a is Professor of Applied Neuroimaging at the University of Edinburgh, Foundation Chair of the UK DRI at Edinburgh, Director of the Row Fogo Centre for research into Ageing and the Brain, and Consultant Neuroradiologist for NHS Lothian. Joanna's full biography is available in the notes at the bottom of this announcement.
IXICO Vascular Biomarker Innovation
The appointments support IXICO's strategy to deepen its presence in Alzheimer's Disease and develop a series of biomarker algorithms to identify and measure vascular abnormalities which are a common contributing factor in neurodegenerative disease where MRI can provide an established biomarker for vascular abnormalities. While particularly relevant for screening, safety and efficacy in AD, measuring vascular components and abnormalities has wider applications in other neurological therapeutic areas such as Cerebral Amyloid Angiopathy (CAA), Stroke, and Multiple Sclerosis. The first in a series of planned vascular biomarker algorithms is already being made available to IXICO clients on their clinical trials with further releases planned for the current financial year.
Robin Wolz, Chief Scientific Officer of IXICO, commented: "It is exciting to be working with Professor Weiner and Professor Wardlaw reflecting IXICO's commitment to advancing the understanding of the interplay between Alzheimer's disease and cerebrovascular pathology. Collaborating with distinguished experts in the field directly supports our work to develop and validate vascular biomarker algorithms that address a critical gap in current AD trials.
By enabling more precise screening, a better understanding of the multiple factors and causes involved in disease, and providing sensitive measures of vascular burden throughout the trial, these biomarkers have the potential to significantly improve trial design and the interpretability of efficacy results. These appointments mark an important step in IXICO's strategy to broaden our biomarker innovation portfolio and deepen our engagement in Alzheimer's disease."
About Michael Weiner, MD
Michael Weiner, MD, is a Professor Emeritus in Radiology and Biomedical Imaging, Medicine, Psychiatry, and Neurology at the University of California, San Francisco. He is Principal Investigator of the Alzheimer's Disease Neuroimaging Initiative, which is the largest observational study in the world concerning Alzheimer's Disease. He is the former Director of the Center for Imaging of Neurodegenerative Diseases (CIND) at the San Francisco Veterans Affairs Medical Center. His overall research goals are to participate in the development of effective treatments and methods for early detection of Alzheimer's disease and other brain disorders. Recently he has focused on developing voice agents for assessments in AD clinical trials.
Michael is the Principal Investigator of the Alzheimer's Disease Neuroimaging Initiative, a 19-year national longitudinal study of over 3,500 subjects which is aimed at validating biomarkers for Alzheimer's disease at 63 sites across the USA and Canada for cognitive testing, MRI, PET, and lumbar puncture. He also launched the BrainHealthRegistry.org which is an internet-based registry with the overall goal of accelerating development of effective treatments for brain diseases. This website registry recruits, screens, and longitudinally monitors brain function on more than 100,000 participants.
Dr. Weiner has mentored over 200 postdoctoral fellows, has authored over 1000 peer reviewed research papers and 71 book chapters. He has received numerous honors including the Young Investigator Award of the American College of Cardiology in 1976, and more recently, the Nancy and Ronald Regan Award from the Alzheimer's Association, the Potamkin Prize of the American Academy of Neurology, a Docteur Honoris Causa Degree from Paul Sabatier University, Toulouse, France in 2019, and the Henry Wisniewski Lifetime Achievement Award in Alzheimer's Disease Research, from the Alzheimer's Association in 2021.
About Professor Joanna Wardlaw, CBE, MB ChB (Hons), MD, FRCR, FRCP, FMedSci, FRSE
Joanna is a is Professor of Applied Neuroimaging at the University of Edinburgh, Foundation Chair of the UK DRI at Edinburgh, Director of the Row Fogo Centre for research into Ageing and the Brain, and Consultant Neuroradiologist for NHS Lothian. Her work focuses on understanding the brain and its blood supply, and treatments to improve blood flow to the brain, including thrombolytic drugs that are now in routine use to treat stroke, and more recently treatments for small vessel disease and vascular dementia. Working with many colleagues, she has been instrumental in advancing understanding of the causes of cerebral small vessel disease and is now testing treatments in clinical trials.
She has set up national research imaging facilities, co-ordinated international research networks, advanced stroke care worldwide and published over 1000 papers. A Fellow of the Royal Society of Edinburgh and the UK Academy of Medical Sciences, she has received awards from many UK and international brain and heart organisations and was made a Commander of the Order of the British Empire (CBE) for services to Medicine and Neuroscience in 2016.
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.